PHASEBIO PHARMACEUTICALS INC's ticker is PHAS and the CUSIP is 717224109. A total of 5 filers reported holding PHASEBIO PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $16,000 | -70.9% | 91,850 | 0.0% | 0.00% | – |
| Q2 2022 | $55,000 | -52.6% | 91,850 | +4.6% | 0.00% | – |
| Q1 2022 | $116,000 | -43.7% | 87,850 | +11.1% | 0.00% | – |
| Q4 2021 | $206,000 | -16.3% | 79,078 | 0.0% | 0.00% | – |
| Q3 2021 | $246,000 | -16.3% | 79,078 | 0.0% | 0.00% | – |
| Q2 2021 | $294,000 | -75.4% | 79,078 | -77.1% | 0.00% | – |
| Q1 2021 | $1,193,000 | +27.7% | 344,657 | +24.0% | 0.00% | – |
| Q4 2020 | $934,000 | -11.6% | 277,957 | -7.6% | 0.00% | – |
| Q3 2020 | $1,056,000 | -11.0% | 300,757 | +16.5% | 0.00% | – |
| Q2 2020 | $1,187,000 | +43.9% | 258,083 | +3.5% | 0.00% | – |
| Q1 2020 | $825,000 | -41.2% | 249,310 | +8.5% | 0.00% | – |
| Q4 2019 | $1,404,000 | +52.1% | 229,779 | +3.9% | 0.00% | – |
| Q3 2019 | $923,000 | -41.1% | 221,242 | +16.6% | 0.00% | – |
| Q2 2019 | $1,567,000 | – | 189,674 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Johnson & Johnson Innovation - JJDC, Inc. | 1,607,044 | $5,400,000 | 0.70% |
| NEA Management Company, LLC | 6,643,704 | $22,323,000 | 0.59% |
| DAFNA Capital Management LLC | 320,542 | $1,077,000 | 0.32% |
| Platform Technology Partners | 141,025 | $474,000 | 0.23% |
| Parkman Healthcare Partners LLC | 110,547 | $371,000 | 0.10% |
| Rock Springs Capital Management LP | 1,314,374 | $4,416,000 | 0.09% |
| GSA CAPITAL PARTNERS LLP | 140,341 | $472,000 | 0.08% |
| SABBY MANAGEMENT, LLC | 65,000 | $218,000 | 0.04% |
| Virtu Financial LLC | 28,821 | $97,000 | 0.01% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 127,600 | $429,000 | 0.01% |